Adial Pharmaceuticals Inc Wt公司档案_Adial Pharmaceuticals Inc Wt股票代码_Adial Pharmaceuticals Inc Wt公司概况 长城基金公司
A 长城基金公司dia 长城基金公司l P 长城基金公司harmaceuticals Inc Wt公司介绍
Adial Pharmaceuticals Inc Wt基本资料
| 证券代码： | ADILW | 上市板： | - |
| 证券名称： | Adial Pharmaceuticals Inc Wt | 上市场所： | 纳斯达克交易所 |
| 证券类型： | - | 发行方式： | - |
| 首发上市日： | 2018/07/27 | 首发价格(元)： | - |
| 首发数量(股)： | - | 首发募资总额(USD/元)： | - |
| 公司名称： | Adial Pharmaceuticals, Inc. | 注册地址： | 美国特拉华州 |
| 证券名称： | Adial Pharmaceuticals Inc Wt | 上市场所： | 纳斯达克交易所 |
| 办公地址： | 1180 Semin 长城基金公司ole Trail, Suite 495, Charlottesville, Virginia, USA | ||
| 董事会主席： | - | 成立日期： | 2010/11/23 |
| 公司属地： | United States 美国 | 电话： | +1 (434) 422-9800 |
| 公司网址： | www.adialpharma.com | ||
| 公司介绍： | Adial Pharmaceuticals, Inc. (formerly: Adial Pharmaceuticals, L.L.C.) (the “Company” or “Adial”) was formed on November 23, 2010 in the Commonwealth of Virginia. Adial is presently engaged in the development and commercializing of medications for the treatment of addictions and related disorders. The Company is planning to commence its first Phase 3 clinical trial of its lead compound ADO4 (“AD04”) for the treatment of alcohol use disorder. Both the U.S. Food and Drug Administration (“FDA”) and the European Medicines Authority (“EMA”) have indicated they will accept to heavy-drinking-based endpoints as a basis approval for the treatment of alcohol use disorder rather than the previously required abstinence-based endpoints. Key patents have been issued in the United States, the European Union, and other jurisdictions for which the Company has worldwide, exclusive license rights. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. Due to its mechanism of action, AD04 has the potential to be used for the treatment of other addictive disorders, such as obesity, smoking, and drug addiction. |
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.smctrader.com/gupiaozhishi/53621.html
本站所有数据资料均来自第三方，仅作为用户获取信息，不构成投资建议，SMC股票学习网不为内容负责。